Friday

24th Nov 2017

Media lift lid on secret reports on drug side-effects

  • The industry says documents of this type are easily misunderstood and misinterpreted. (Photo: www.freeimages.co.uk)

Adverse reactions to medication is the fifth most common cause of death in hospitals according to the European Commission, but EU agencies and national governments have until now kept secret pharmaceutical companies' reports on side-effects.

The notes - known in the business as Periodic Safety Update Reports (PSURs) - are submitted regularly to national authorities and the European Medicines Agency in London.

Thank you for reading EUobserver!

Subscribe now for a 30 day free trial.

  1. €150 per year
  2. or €15 per month
  3. Cancel anytime

EUobserver is an independent, not-for-profit news organization that publishes daily news reports, analysis, and investigations from Brussels and the EU member states. We are an indispensable news source for anyone who wants to know what is going on in the EU.

We are mainly funded by advertising and subscription revenues. As advertising revenues are falling fast, we depend on subscription revenues to support our journalism.

For group, corporate or student subscriptions, please contact us. See also our full Terms of Use.

If you already have an account click here to login.

The PSURs for example detail how doctors in various countries suspect that teenagers grow suicidal when taking a certain medication against pimples, or that a diet product could lead to a stroke and what industry has to say about the medical fears.

A team of Dutch, Danish and Belgian journalists has now used freedom of information legislation in the Netherlands and Denmark to get partial access to the documents, where patient gender, age and country of origin are blacked out to protect privacy and business interests. A legal decision is pending in Belgium.

The move by Dutch daily newspaper Trouw, Belgian magazine Knack in cooperation with Danish magazine Samvirke to put the documents on the internet comes as the European Commission on Tuesday (22 October) decided to delay the publication of a new package of regulation for drugs producers.

The commission package is not expected to mandate publication of PSURs but is likely to allow pharmaceutical companies to contact patients directly - a practice that is currently illegal and was condemned by the European Parliament in 2002.

"In my view, there can be no doubt that PSURs should be made public. After all this is about the side-effects on medicines that we take," Margrethe Nielsen, a researcher at the Cochrane Institute's Copenhagen branch and a specialist on pharmaceuticals told EUobserver.

She added that the notes, which form the basis of government understanding of the sector, are not based on clinically controlled tests method. "This is maybe the most important: this does not build on sound science," she said. "I would not be able to use them for my work."

"In these reports [released in the Netherlands and Denmark] much too much has been blackened. The quality is unequal. It is of big importance that these safety reports can be accessible for everybody so that scientists can debate about their quality," Canadian expert Barbara Mintzes told Knack.

Reacting in a test case on PSUR publication in Denmark in 2007, lawyers for drug firm Roche threatened to sue the Danish state if disclosure harmed the company's commercial interests.

"A competitor can use the reports as a basis for guidance to patients and guidance to doctors. Competitors can with the help of PSUR reports obtain a basis to take care of guiding functions, that can weaken Roches position on the market and thus bring significant negative economic effects for Roche worldwide," the company's legal advisors wrote in letters to Danish authorities.

"Experience shows, that documents of this type are easily misunderstood and misinterpreted, for example by journalists," the letters add. "Misunderstandings of this type can cause severe disturbance of the market and thus loss for Roche."

The view is shared by the Brussels-based trade lobby, the European Federation of Pharmaceutical Industries and Associations (EFPIA), today.

"The trouble is, they have to be understandable. You need to be an expert, to understand them. I would push that back to the regulator to take proper action. When you pull information, it has to be in a form, that you and I can understand," EFPIA director Brian Ager said.

"The industry claims that the people wouldn't understand them. In reality making the side effects public would influence the stock exchange in a negative way," French medical journal Prescire's editor Bruno Toussaint said.

Mali blames West for chaos in Libya

Mali's foreign minister Abdoulaye Diop told the EU in Brussels that the lack of vision and planning following the Nato-led bombing campaign in Libya helped trigger the current migration and security crisis.

Opinion

The EU's half-hearted Ostpolitik

If, as the EU claims, the Eastern Partnership summit is not a format for conflict resolution, where else will the security issues that hold the region back be resolved?

Stakeholders' Highlights

  1. Nordic Council of MinistersNordic Energy Ministers Pledge to Work More Closely at Nordic and EU Level
  2. European Friends of ArmeniaLaunch of Honorary Council on the Occasion of the Eastern Partnership Summit and CEPA
  3. International Partnership for Human RightsEU Leaders Should Press Azerbaijan President to End the Detention of Critics
  4. CECEKey Stakeholders to Jointly Tackle the Skills Issue in the Construction Sector
  5. Idealist Quarterly"Dear Politics, Time to Meet Creativity!" Afterwork Discussion & Networking
  6. Mission of China to the EUAmbassador Zhang Ming Received by Tusk; Bright Future for EU-China Relations
  7. EU2017EEEstonia, With the ECHAlliance, Introduces the Digital Health Society Declaration
  8. ILGA EuropeFreedom of Movement For All Families? Same Sex Couple Ask EU Court for Recognition
  9. European Jewish CongressEJC to French President Macron: We Oppose All Contact With Far-Right & Far-Left
  10. EPSUWith EU Pillar of Social Rights in Place, Time Is Ticking for Commission to Deliver
  11. ILGA EuropeBan on LGBTI Events in Ankara Must Be Overturned
  12. Bio-Based IndustriesBio-Based Industries: European Growth is in Our Nature!

Latest News

  1. EU awaits UK proposals in final push for Brexit breakthrough
  2. Berlin risks being 'culprit' for stalling EU, warns Green MEP
  3. Eastern partners, eastern problems
  4. Germany's Schulz under pressure to enter coalition talks
  5. LuxLeaks trial re-opens debate on whistleblowers' protection
  6. Wilders says Russia is 'no enemy' ahead of Moscow visit
  7. EU must put Sudan under microscope at Africa summit
  8. Mali blames West for chaos in Libya